Therapeutic Challenges Associated with Extended‐Spectrum, β‐Lactamase‐Producing Escherichia coli and Klebsiella pneumoniae
Author:
- 1 May 2001
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 21 (5) , 583-592
Abstract
The emergence of extended‐spectrum β‐lactamase (ESBL)‐producing Enterobacteriaceae, particularly Escherichia coli and Klebsiella pneumoniae , presents significant diagnostic and therapeutic challenges to the management of infections due to these organisms. Detection of resistant isolates is difficult based on routine susceptibility testing performed by a clinical microbiology laboratory. In addition, the utility of penicillins, cephalosporins, and aztreonam in treating serious infections due to these organisms is uncertain due to reports of treatment failure despite apparent in vitro susceptibility. A critical evaluation of the English literature was performed on treatment outcomes associated with ESBL‐producing Enterobacteriaceae. Imipenem and extended‐spectrum cephalosporins were commonly administered. Discordant outcomes in relation to in vitro susceptibility of the agent did not occur exclusively with cephalosporins but with all drugs including imipenem. Until more outcome data are available, drug selection must take into consideration whether or not an outbreak is occurring and whether therapy is empirical or definitive.Keywords
This publication has 43 references indexed in Scilit:
- Editorial Response: Extended-Spectrum -Lactamases: A Call for Improved Detection and ControlClinical Infectious Diseases, 1999
- Successful Treatment of Ceftazidime‐Resistant Klebsiella pneumoniae Ventriculitis with Intravenous Meropenem and Intraventricular Polymyxin B: Case Report and ReviewClinical Infectious Diseases, 1999
- Comparative Activity of Piperacillin/Tazobactam against Clinical Isolates of Extended- Spectrum β-Lactamase-Producing EnterobacteriaceaeChemotherapy, 1998
- Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United StatesDiagnostic Microbiology and Infectious Disease, 1998
- In vitro Time-Kill Curves of Cefepime and Cef pirome Combined with Amikacin, Gentamicin or Ciprofloxacin against Klebsiella pneumoniae Producing Extended-Spectrum Beta-LactamaseChemotherapy, 1997
- Is it important to identify extended-spectrum beta-lactamase-producing isolates?European Journal of Clinical Microbiology & Infectious Diseases, 1996
- Bactericidal effect of β-lactams and amikacin alone or in association against Klebsiella pneumoniae producing extended spectrum β-lactamaseJournal of Antimicrobial Chemotherapy, 1995
- Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactamThe Lancet, 1994
- Novel β-lactamase in a clinical isolate of Klebsiella pneumoniae conferring unusual resistance to β-lactam antibioticsJournal of Antimicrobial Chemotherapy, 1987
- TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAEThe Lancet, 1987